0041 GMT - ResMed's bulls at Jarden see potential for the breathing-tech maker's 4Q gross margin to surprise to the upside. Analysts Steve Wheen and Tristan Maher forecast on-quarter margin expansion of 20 bps, but tell clients in a note that an even greater improvement is possible. They cite manufacturing and distribution efficiencies, product mix, scale advantages and currency tailwinds as reasons for their optimism. While their 60.1% margin forecast is in line with consensus, they observe that a result of 60.5% would lift EPS by 1.3% relative to their forecasts. Jarden has an overweight rating and A$40.55 target price on the stock, which is down 0.1% at A$39.48. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
July 17, 2025 20:41 ET (00:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.